Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746138 | 1.00 | SCN10A (0.40) | SCN10AKCNH2SSTR3MAPK13MAPK12 | |
| SCHEMBL12175283 | 0.89 | MAPK13 (0.40) | SCN10AKCNH2SSTR3MAPK13MAPK12 | |
| SCHEMBL13635780 | 0.89 | MAPK13 (0.40) | SCN10AKCNH2SSTR3MAPK13MAPK12 | |
| SCHEMBL13635781 | 0.88 | KCNH2 (0.41) | SCN10AKCNH2SSTR3MAPK13MAPK12 | |
| SCHEMBL12175132 | 0.88 | KCNH2 (0.41) | SCN10AKCNH2SSTR3MAPK13MAPK12 | |
| SCHEMBL9280936 | 0.85 | MAPK13 (0.47) | SCN10AKCNH2SSTR3MAPK13MAPK12 | |
| SCHEMBL9284198 | 0.85 | MAPK13 (0.47) | SCN10AKCNH2SSTR3MAPK13MAPK12 | |
| SCHEMBL15848551 | 0.84 | SSTR3 (0.50) | SCN10AKCNH2SSTR3MAPK13MAPK12 | |
| SCHEMBL15848552 | 0.84 | SSTR3 (0.50) | SCN10AKCNH2SSTR3MAPK13MAPK12 | |
| SCHEMBL2775603 | 0.84 | MAPK13 (0.46) | SCN10AKCNH2SSTR3MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8303944-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-8303944-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | SCN10A 4625/4885KCNH2 4523/4885SSTR3 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.